Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancer

15 Sept 2017

Abstract excerpt

// Katharina Prieske 1, * , Stefan Prieske 1, * , Simon A. Joosse 2 , Fabian Trillsch 3 , Donata Grimm 1 , Eike Burandt 4 , Sven Mahner 3 , Barbara Schmalfeldt 1 , Karin Milde-Langosch 1 , Leticia Oliveira-Ferrer 1 and Linn Woelber 1 1 Department of Gynecology and Gynecologic Oncology, University Medical Centre Hamburg-Eppendorf, 20246 Hamburg, Germany 2 Department of Tumor Biology, University Medical Centre...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ovarian cancer diagnosis and treatment
Share to PARP inhibition in cancer therapy
Share to Reproductive Biology and Fertility

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 29137324
DOI: 10.18632/oncotarget.20945

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of BRCA1 promotor hypermethylation in recurrent high-grade ovarian cancerPMID 29137324Read ↗

BRCA loss of function including BRCA1 DNA-methylation, but not BRCA-unrelated homologous recombination deficiency, is associated with platinum hypersensitivity in high-grade ovarian cancer.Semantic proximity Read ↗

Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer.Semantic proximity Read ↗

Characterisation of homologous recombination deficiency in paired primary and recurrent high-grade serous ovarian cancerSemantic proximity Read ↗

The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 studySemantic proximity Read ↗

Distinct genomic profiles are associated with treatment response and survival in ovarian cancerSemantic proximity Read ↗

Genomic alterations enable <i>BRCA1</i> methylation loss and promoter bypass to drive resistance in high-grade serous ovarian cancerSemantic proximity Read ↗

<i>BRCA1</i>epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancerSemantic proximity Read ↗

Molecular profiles of BRCA1-associated ovarian cancer treated by platinum-based therapy: Analysis of primary, residual and relapsed tumors.Semantic proximity Read ↗

Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.Semantic proximity Read ↗

DNA Methylation and Transcriptomic Features are Preserved Throughout Disease Recurrence and Chemoresistance in High Grade Serous Ovarian CancersSemantic proximity Read ↗

Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapySemantic proximity Read ↗

Maintenance therapy for recurrent epithelial ovarian cancer: current therapies and future perspectives - a review.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.